Clustering of intuitive eating and psychological health identifies subgroups associated with weight loss following semaglutide

Obesity (Silver Spring). 2025 May;33(5):892-902. doi: 10.1002/oby.24262. Epub 2025 Apr 3.

Abstract

Objective: Obesity management requires personalized approaches. Using data from the Aviitam platform in France, this study aimed to do the following: 1) explore psychological and behavioral patterns through clustering techniques; 2) validate the robustness of these clusters; and 3) assess their association with weight-loss outcomes in severe obesity under semaglutide treatment.

Methods: Phase 1 included 989 adults with BMI ≥ 25 kg/m2 who completed validated questionnaires, including the Hospital Anxiety and Depression Scale (HADS) and Intuitive Eating Scale-2 (IES-2). Phase 2 validated robustness in 492 individuals. Phase 3 applied clusters to 125 individuals with BMI ≥ 40 kg/m2 who were treated with semaglutide 2.4 mg/week at Montpellier University Hospital, assessing weight-loss trajectories over 12 months.

Results: The following two clusters were identified: the Intuitive Eaters Group (IEG, n = 482); and the Emotionally Driven Eaters Group (EDEG, n = 507). The IEG exhibited lower emotional distress and higher intuitive eating scores. HADS and IES-2 distinguished clusters effectively (area under the curve, 0.95). Robustness was confirmed in Phase 2. In Phase 3, the IEG demonstrated a significantly more favorable weight-loss trajectory compared to the EDEG (p = 0.03).

Conclusions: Psychological and behavioral clusters identified through HADS and IES-2 are associated with weight loss under semaglutide treatment, suggesting the value of integrating psychological and behavioral profiling into obesity care.

MeSH terms

  • Adult
  • Anti-Obesity Agents* / therapeutic use
  • Body Mass Index
  • Cluster Analysis
  • Feeding Behavior* / psychology
  • Female
  • France
  • Glucagon-Like Peptide 1
  • Glucagon-Like Peptides* / therapeutic use
  • Humans
  • Male
  • Mental Health*
  • Middle Aged
  • Obesity* / drug therapy
  • Obesity* / psychology
  • Obesity, Morbid* / drug therapy
  • Obesity, Morbid* / psychology
  • Semaglutide
  • Surveys and Questionnaires
  • Weight Loss* / drug effects

Substances

  • Glucagon-Like Peptides
  • Anti-Obesity Agents
  • Glucagon-Like Peptide 1
  • Semaglutide